Biogen (BIIB)
| Company | Ticker | Sector | Industry | Quality | PAR |
|---|---|---|---|---|
| Biogen | BIIB | Healthcare | Drug Manufacturers - General | 92 | 11.6% |
| Current Price (09/17) | $300.19 | |||
| CAPS Rating (Rate this stock on CAPS) |  |
|||
| Expected Income Statement | ||||
| Current Sales | 10,077.0 | |||
| Sales Growth Forecast | 9.6% | |||
| Net Profit Margin | 28.5% | |||
| Projected Shares Outstanding | 139.97 | |||
| EPS - Five year Forecast | $32.43 | |||
| Average P/E Ratio | 16.0 | |||
| Projected Average Price | $518.88 | |||
| Price Appreciation (Annualized) | 11.6% | |||
| Annual Dividend Yield | 0.0% | |||
| Projected Annual Return | 11.6% | |||
| Quality | ||||
| Financial Strength | 90 | 22.5 | ||
| EPS Stability | 85 | 21.3 | ||
| Industry Sales Growth Rate | 8.0% | 15.0 | ||
| Industry Net Profit Margin | 22.5% | 15.8 | ||
| Calculated Quality Rating | 74.6 | |||
| Fool CAPS | ||||
Total Players
964
Outperforms
74
Underperforms
All-Stars (213)
202
Outperforms (95%)
11
Underperforms
|
||||
| Fundamental Data Updated: 07/02/2021 | ||||